

Table S1 Baseline characteristics

Variable	Excluded patients without baseline in OCT-guidance (n=216)	Excluded patients without OCT-guidance (n=340)	P
Age, years	63.38±10.47	63.67±10.50	0.74
Male	173 (80.1)	271 (79.7)	>0.99
Current smoker	99 (45.8)	161 (47.4)	0.72
Hypertension	133 (61.6)	209 (61.5)	>0.99
Diabetes mellitus	55 (25.6)	95 (28.1)	0.55
Chronic cardiac insufficiency	9 (4.2)	12 (3.5)	0.82
Clinical presentation			0.93
STEMI	29 (13.4)	44 (12.9)	
NSTEMI	12 (5.6)	16 (4.7)	
UA	19 (8.8)	34 (10.0)	
Stable AP	156 (72.2)	246 (72.4)	
Laboratory findings			
White blood cells, ×10 ⁹ /L	7.08 [5.72–8.68]	7.06 [5.78–8.42]	0.87
Hemoglobin, g/L	140.05±18.23	140.01±17.44	0.98
Platelet, ×10 ⁹ /L	199.50 [154.00–239.75]	203.50 [154.75–239.75]	0.85
ALT, U/L	26.00 [19.00–36.00]	25.50 [18.00–35.75]	0.53
AST, U/L	30.00 [23.00–40.00]	29.00 [23.00–38.00]	0.58
Total bilirubin, μmol/L	12.45 [9.33–17.00]	12.20 [9.00–16.70]	0.60
Direct bilirubin, μmol/L	2.85 [2.10–3.90]	2.80 [2.00–3.90]	0.67
NT-proBNP, pg/mL	223.50 [94.58–686.75]	206.35 [92.05–667.45]	0.64
eGFR, mL/min/1.73 m ²	79.90 [60.69–99.51]	78.78 [59.51–102.31]	0.92
Triglycerides, mmol/L	1.55 [1.17–2.43]	1.51 [1.17–2.40]	0.84
Total cholesterol, mmol/L	3.88 [3.30–4.83]	3.88 [3.29–4.83]	0.93
HDL-C, mmol/L	1.08 [0.91–1.24]	1.08 [0.90–1.23]	0.98
LDL-C, mmol/L	2.27 [1.84–2.83]	2.25 [1.84–2.83]	0.87
apoA-I, mmol/L	1.19 [1.06–1.32]	1.18 [1.06–1.33]	0.87
apoB, mmol/L	0.69 [0.58–0.87]	0.70 [0.59–0.88]	0.92
Medicine use			
Aspirin	204 (94.4)	321 (94.4)	>0.99
Clopidogrel	195 (90.3)	302 (88.8)	0.67
Statin	191 (88.4)	307 (90.3)	0.48

Data are presented as mean ± standard deviation, median [interquartile range] or n (%). STEMI, ST-segment elevation myocardial infarction; NSTEMI, Non-ST Segment Elevation Myocardial Infarction; UA, unstable angina pectoris; Stable AP, stable angina pectoris; ALT, alanine aminotransferase; AST, aspartate aminotransferase; NT-proBNP, N-terminal pro-B-type natriuretic peptide; eGFR, estimated glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; apoA-I, apolipoprotein A-I; apoB, apolipoprotein B.

Table S2 Angiography characteristics

Variable	Tertile 1 (n=71) (HAR ≤0.836)	Tertile 2 (n=73) (0.836< HAR <0.932)	Tertile 3 (n=72) (HAR ≥0.932)	P
Time since implantation, years	3 [1–5]	2 [1–5]	3.5 [1–8]	0.12
Culprit vessel				0.39
Left anterior descending	43 (60.6)	52 (71.2)	42 (58.3)	
Circumflex	4 (5.6)	6 (8.2)	8 (11.1)	
Right	23 (32.4)	15 (20.5)	21 (29.2)	
Other	1 (1.4)	0 (0.0)	1 (1.4)	
Lesion characteristics				
Bifurcation (>1.5 mm)	16 (22.5)	18 (24.7)	14 (19.4)	0.75
Ostial location	6 (8.5)	7 (9.6)	2 (2.7)	0.22
In-stent restenosis pattern*				0.80
Type I	20 (28.2)	16 (21.9)	22 (30.6)	
Type II	14 (19.7)	20 (27.4)	19 (26.4)	
Type III	18 (25.4)	19 (26.0)	14 (19.4)	
Type IV	19 (26.8)	18 (24.7)	17 (23.6)	

Data are presented as median [interquartile range] or n (%). *, in-stent restenosis pattern was defined as per Mehran's classification.